The following studies might have something to do with the interest that Novartis has in PMR/GCA. They must be seeing good results:
https://www.novartis.com/clinicaltrials/study/nct06130540
and
https://www.novartis.com/clinicaltrials/study/nct06331312
---------------------------
My rheumatologist has already mentioned COSENTYX® (secukinumab) to me because I have Spondyloarthritis and PMR.
--------------------------
I loved this part of the abstract:

"Sentiment of pts around various treatments (n=297) available for PMR and GCA was negative (61%), mostly driven by side effects/intolerability, inefficacy/waning efficacy and flare-ups during steroid tapering. From the overall responses related to treatment perceptions (n=41), glucocorticoids (GC) had a relatively negative perception (35%), whereas biologics had a more positive perception (27%) and were perceived as a safer alternative by pts. The burden of comorbidities associated with the use of GCs was also a recurrent concern."